Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Perlyn Zekui Kwek"'
Autor:
Joma Joy, David Quach, Priya Retna, Klement Foo, Boping Liu, John Liang Kuan Wee, Anders Poulsen, Guanghui Tang, Shao Q. Yao, Perlyn Zekui Kwek, Nithya Baburajendran, Wan-Qi Yang, Jothi Anantharajan, Thomas H. Keller, Rong Li, Chong-Jing Zhang, Doris Hui Ying Tee
Targeted covalent inhibitors have re-emerged as validated drugs to overcome acquired resistance in cancer treatment. Herein, by using a carbonyl boronic acid warhead, we report the structure-based design of BCR-ABL inhibitors via reversible covalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::171ce237421bc22447f3c94c78646d05
https://doi.org/10.26434/chemrxiv.13710097
https://doi.org/10.26434/chemrxiv.13710097
Autor:
Hui Qi Ng, Shuang Liu, Yan Li, Jeffrey Hill, CongBao Kang, Perlyn Zekui Kwek, Yih Wan Tan, Joma Joy, Alvin W. Hung, Thomas H. Keller, Anna Ngo
Publikováno v:
Biomolecular NMR Assignments. 11:225-229
NSD3 is a histone H3 methyltransferase that plays an important role in chromatin biology. A construct containing the methyltransferase domain encompassing residues Q1049-K1299 of human NSD3 was obtained and biochemical activity was demonstrated using
Autor:
Alvin W. Hung, John Liang Kuan Wee, Yvonne Tan, Jianhe Peng, Jung Hyun Min, Rong Li, Wei Guang Seetoh, Horst Flotow, Anna Ngo, Liling Wu, Ernesto Guccione, Joma Joy, Xiaoying Koh-Stenta, Yoonjung Shim, Jing Cao, Jeffrey Hill, Umayal Lakshmanan, Perlyn Zekui Kwek, Anders Poulsen
Publikováno v:
Biochemical Journal. 461:323-334
PRDM proteins have emerged as important regulators of disease and developmental processes. To gain insight into the mechanistic actions of the PRDM family, we have performed comprehensive characterization of a prototype member protein, the histone me
Autor:
Xiaoying Koh-Stenta, Perlyn Zekui Kwek, Sin Yin Chew, Jeffrey Hill, Anders Poulsen, Rong Li, Liling Wu, Ernesto Guccione, Joma Joy, John Liang Kuan Wee, Jianhe Peng
Publikováno v:
The Biochemical journal. 474(6)
We have previously characterised the histone lysine methyltransferase properties of PRDM9, a member of the PRDM family of putative transcriptional regulators. PRDM9 displays broad substrate recognition and methylates a range of histone substrates, in
Autor:
Vithya Manoharan, Esther H. Q. Ong, John Lw Kuan, Jeffrey Hill, Thomas H. Keller, Shi Jing Tai, Lohitha Rao Chennamaneni, Sharon Xiaodai Lim, Athisayamani Jeyaraj Duraiswamy, Haiyan Yang, Kanda Sangthongpitag, Boping Liu, Charles Chuah, Kassoum Nacro, Joma Joy, Meng Ling Choong, Eldwin Sum Wai Tan, May Ann Lee, Yoon Sheng Yeap, Alex Matter, Perlyn Zekui Kwek, Vishal Pendharkar, Shi Hua Ang, Tiong S. Ong, Lijun Ding, Melvyn Ho, Yun Shan Chew, Anders Poulsen
Publikováno v:
Cancer Research. 76:2134-2134
The marketed BCR-ABL tyrosine kinase inhibitor (TKI), imatinib (Gleevec™) is a very successful targeted anti-cancer therapy. It has revolutionized the treatment of early stage or chronic phase (CP) chronic myeloid leukemia (CML). Unfortunately, a p
Autor:
Kah Fei Wan, Xiaoying Koh-Stenta, Anders Poulsen, Joma Joy, Perlyn Zekui Kwek, John Liang Kuan Wee, May Ann Lee, Jeffrey Hill, Subhash G. Vasudevan, Shovanlal Gayen, Angela Shuyi Chen, Kassoum Nacro, CongBao Kang, Si Fang Wang
Publikováno v:
Drug Design, Development and Therapy
Xiaoying Koh-Stenta,1 Joma Joy,1 Si Fang Wang,1 Perlyn Zekui Kwek,1 John Liang Kuan Wee,1 Kah Fei Wan,2 Shovanlal Gayen,1 Angela Shuyi Chen,1 CongBao Kang,1 May Ann Lee,1 Anders Poulsen,1 Subhash G Vasudevan,3 Jeffrey Hill,1 Kassoum Nacro11Experiment
Autor:
Jun Ding Li, Samantha Guo, Zhi Ying Poh, Vithya Manoharan, Melvyn Ho, Esther H. Q. Ong, Joma Joy, Kassoum Nacro, Joseph Cherian, Yun Shan Chew, Sharon Xiaodai Lim, Alex Matter, Perlyn Zekui Kwek, May Ann Lee, Meng Ling Choong, S. Tiong Ong, Siew Peng Tan, Jeffrey Hill, Vishal Pendharkar, Kannan Srinivararaghavan, Kanda Sangthongpitag, Anders Poulsen, Thomas H. Keller, Haiyan Yang, Boping Liu, Charles Chuah
Publikováno v:
Blood. 122:2702-2702
Pharmacologic inhibition of BCR-ABL by tyrosine kinase inhibitors (TKI) provides effective therapy for chronic phase but not blast crisis (BC) CML. The inability of TKIs to control BC CML is due to the reactivation of BCR-ABL through TKI resistance-c